An international acquirer signs a term sheet for an Israeli technology target, confident the deal will close within three months. Six months later, the process is still open. delayed by undisclosed regulatory approvals. A share purchase agreement that did not account for Israeli corporate legislation requirements. Additionally, due diligence findings that surfaced only after exclusivity had been granted. The cost of that sequence is not just time. It is leverage, credibility, and in some cases the transaction itself.
M&A transactions in Israel involve a structured process governed by Israeli corporate legislation and, where applicable, securities law and sector-specific regulatory rules. A share purchase agreement (SPA) or asset purchase agreement must address representations and warranties, closing conditions, and mandatory regulatory clearances before completion can occur. Timelines for straightforward private transactions typically run from three to six months; deals involving regulated sectors, public companies, or foreign investment considerations take longer.
This page covers the principal legal instruments available to international buyers and sellers in Israel, the procedural steps from letter of intent to closing. Common pitfalls that derail cross-border transactions. Additionally, the strategic considerations that arise when EU or UAE counterparties are involved.
The regulatory setting for M&A in Israel
Israeli corporate legislation – primarily the Companies Law – governs the structural mechanics of acquisitions involving Israeli companies. It sets out the conditions under which share transfers, mergers. Additionally, asset sales are valid. The rights of shareholders who dissent from a proposed transaction. Additionally, the thresholds above which board and shareholder approval is required.
Beyond the Companies Law, several other branches of Israeli law bear directly on M&A activity. Competition law requires pre-merger notification to the Israeli Competition Authority when the combined turnover or market share of the parties exceeds defined thresholds. Failure to notify – or closing before clearance – can result in mandatory unwinding of the transaction. In technology-related sectors, export control rules administered under Israeli defence export legislation may require government approval where the target holds dual-use technologies or certain defence-adjacent intellectual property.
Israel's securities legislation applies to transactions involving publicly traded companies on the Tel Aviv Stock Exchange (Bursa HaYekarot B'Tel Aviv – the Tel Aviv Stock Exchange, known as TASE). Tender offer rules, disclosure obligations, and mandatory bid thresholds all apply once a buyer crosses defined ownership levels. A client accustomed to UK Takeover Code procedures or EU Transparency Directive requirements will find structural analogies in Israeli securities law, but the procedural details differ enough to require dedicated local analysis.
For transactions in the financial services sector, banking regulation administered by the Bank of Israel adds a further approval layer. Similar sectoral licensing requirements exist for insurance, communications, and certain energy assets. International buyers frequently underestimate the lead time these approvals introduce – in some sectors, regulatory review alone runs four to eight months.
Understanding which regulatory regimes apply before the letter of intent is signed is not a formality. It is a fundamental deal-structuring decision. If a required approval is not built into the timeline and closing conditions from the outset, the entire deal timetable must be rebuilt mid-process – usually at the cost of renegotiated price or terms.
Israeli corporate law matters that precede or run alongside M&A processes – including company governance reviews, board resolutions, and shareholder agreement analysis – are covered in detail in our corporate law service for Israel.Key instruments: from heads of terms to closing
Israeli M&A transactions follow a recognisable sequence, but each stage carries specific legal content that determines whether the deal ultimately closes on acceptable terms.
Letter of intent or term sheet. The initial document sets out the headline economics and the exclusivity period. Under Israeli contract law, a letter of intent can create binding obligations even when labelled non-binding, if its language indicates agreement on essential terms. Practitioners in Israel note that courts have held preliminary agreements to be enforceable where the parties' conduct demonstrated reliance. International buyers should treat the term sheet as a document with potential legal effect, not merely a commercial summary.
Due diligence. Due diligence in Israeli transactions covers legal, financial, tax, and technical streams. For technology companies – which represent a significant share of cross-border Israeli deal flow – IP due diligence is particularly critical. Israeli law governs ownership of inventions created by employees, and the default rules under employment legislation may vest certain rights in the inventor rather than the employer unless a written assignment agreement is in place. A gap in IP assignment documentation at the due diligence stage is one of the most common deal-breakers in Israeli tech acquisitions.
Tax due diligence must address Israeli capital gains treatment, the availability of tax rulings from the Israeli Tax Authority, and any pre-existing benefits under Israeli investment legislation. Companies that received grants or benefits from the Israel Innovation Authority may be subject to repayment obligations or approval requirements on a change of control. These obligations do not disappear on closing – they transfer to the buyer.
The share purchase agreement. The SPA is the central legal instrument. Under Israeli practice, the SPA will contain representations and warranties given by the seller, conditions precedent to closing, indemnification provisions, and post-closing adjustment mechanisms. Representations and warranties in Israeli SPAs track international standards in structure but must reflect Israeli-specific concepts: the status of share capital under the Companies Law. The effect of a company's articles of association (takanon. the constitutional document of an Israeli company). Additionally, the treatment of employee rights on a change of control.
Closing conditions typically include receipt of all required regulatory approvals, confirmation that no material adverse change has occurred, and delivery of required corporate authorisations. International buyers should ensure that the definition of material adverse change in the SPA is drafted with Israeli law in mind. The concept is not codified in Israeli legislation, and its interpretation by Israeli courts draws on a mix of contractual construction principles and general civil law doctrine.
Earn-out provisions are used in a significant share of Israeli technology acquisitions, particularly where valuation disagreements arise between parties. Israeli courts have addressed the enforceability of earn-out mechanisms, and practitioners note that ambiguity in the earn-out formula is a frequent source of post-closing disputes. The formula, measurement period, and buyer's obligations to support the target's performance during the earn-out period all require precise drafting.
Warranty and indemnity insurance is increasingly used in Israeli deals, particularly where the seller is a venture capital fund wishing to achieve a clean exit. The availability and pricing of this product in the Israeli market should be assessed early in the deal, as it affects how representations and warranties are negotiated.
To discuss how the SPA structure and closing conditions apply to your specific transaction in Israel, contact us at info@ferrazwhitmore.com.
Practical pitfalls in Israeli M&A transactions
Several issues arise repeatedly in cross-border Israeli transactions. Awareness of them at the outset materially reduces the risk of late-stage complications.
Employee rights on a change of control. Israeli employment legislation provides employees with significant protections. On an asset acquisition, employees do not automatically transfer to the buyer – each employment relationship must be individually addressed. On a share acquisition, employment contracts transfer with the company, but existing entitlements – including severance pay rights under Israeli labour law – continue to accrue. International buyers who structure a transaction as an asset deal to avoid employee liabilities often discover that the operational cost of re-hiring essential staff outweighs the perceived benefit.
Israel Innovation Authority obligations. Many Israeli technology companies have received grants from the Israel Innovation Authority (IIA). Those grants are subject to conditions that survive a change of control. A transfer of ownership to a foreign entity may require IIA approval and, in some cases, the payment of a royalty or a lump-sum obligation based on the grant amount. Buyers who do not identify and quantify IIA obligations in due diligence can face unexpected post-closing costs that were not priced into the transaction.
Minority shareholder rights. Israeli corporate legislation provides minority shareholders with oppression remedies that can be invoked to challenge a transaction. In private company acquisitions involving multiple shareholders, the SPA must include a mechanism – typically drag-along rights in the company's articles or a separate shareholder agreement – to bind all shareholders to the agreed terms. If drag-along provisions have not been properly documented in the target's constitutional documents, the buyer may find it cannot acquire 100% of the company without litigation.
Tax rulings and withholding. Gains on the sale of Israeli company shares are subject to Israeli capital gains tax in the hands of the seller. Where the seller is a foreign entity, the buyer may be required to withhold tax at source unless the seller obtains a withholding certificate from the Israeli Tax Authority confirming a reduced or zero rate. This process can take several weeks. If it is not initiated at an early stage, it can delay closing or create unexpected financial exposure for the buyer as the party responsible for withholding.
Antitrust timing. The Israeli Competition Authority's merger review process has its own procedural timeline. Unlike certain EU competition procedures, the Israeli regime does not provide a hard-stop statutory deadline in all cases. Parties who build the deal timetable around an optimistic review period and then encounter a more detailed investigation phase must extend their exclusivity and maintain deal costs for longer than anticipated.
Governing law and dispute resolution. Most Israeli SPAs are governed by Israeli law and provide for resolution of disputes in Israeli courts. Where one party is a foreign entity, this can create practical difficulties in enforcement. Some cross-border transactions – particularly those involving a US or EU counterpart – incorporate international arbitration as an alternative. The choice of dispute resolution mechanism has implications for confidentiality, enforceability of awards, and interim relief. It should be agreed at the term sheet stage, not left to the SPA negotiation.
Cross-border and strategic considerations: UAE and EU dimensions
Israeli M&A has a pronounced cross-border dimension. Following the Abraham Accords, transaction volume between Israeli companies and counterparties from the UAE and other Gulf states has increased substantially. At the same time, Israeli targets continue to attract European acquirers, and Israeli companies continue to list on European and US exchanges.
UAE acquirers and investors. A UAE-based acquirer purchasing an Israeli company must consider both Israeli regulatory requirements and UAE corporate governance rules governing outbound investments. Where the UAE entity is a free zone company, the scope of its permitted activities and its ability to hold foreign equity may be regulated under the applicable free zone authority's rules. At the Israeli end, the transaction is subject to the same regulatory clearances as any other foreign acquisition. Sector-specific Israeli restrictions on foreign ownership in certain industries apply regardless of the acquirer's nationality.
For clients whose transactions involve parallel activity in the UAE, our analysis of M&A transactions in the UAE addresses the relevant instruments, regulatory environment, and practical steps on the UAE side.
EU acquirers and investors. European buyers of Israeli assets must assess whether the transaction constitutes a foreign direct investment (FDI) that requires notification or approval under the buyer's home jurisdiction FDI screening regime. Several EU member states have broadened their FDI rules in recent years to capture acquisitions in technology and critical infrastructure sectors – precisely the sectors where Israeli targets are most active. A transaction that is straightforward from an Israeli regulatory perspective may still require clearance in Germany, France, or another EU jurisdiction before closing.
EU buyers should also consider the tax treatment of the acquisition in their home jurisdiction. Israeli tax treaties with EU member states vary in their coverage of capital gains, dividends, and royalties. The structure of the acquisition – whether through a holding company, a direct purchase, or a joint venture – affects the long-term tax efficiency of the investment. Early tax structuring advice, covering both Israeli and EU dimensions, is an integral part of deal preparation rather than an afterthought.
Dual-listed companies. Israeli companies listed on TASE and a foreign exchange – typically NASDAQ – are subject to parallel disclosure and takeover obligations. An acquisition of a dual-listed company requires compliance with Israeli securities law and the rules of the foreign exchange simultaneously. The interaction between these two sets of rules is a specialist area that requires coordinated advice across both jurisdictions.
Post-closing integration. Cross-border acquisitions of Israeli technology companies frequently involve the migration of IP or the relocation of research and development functions. Under Israeli tax legislation and IIA rules, both of these activities may require regulatory approval and may trigger tax or repayment obligations. Post-closing integration planning should therefore be addressed in the SPA, including through representations about the absence of restrictions on IP migration and specific indemnities if approvals cannot be obtained.
For a tailored strategy on cross-border M&A involving Israeli and international counterparties, reach out to info@ferrazwhitmore.com.
Self-assessment: is this transaction structure right for your situation?
Before committing to a share purchase structure in Israel, verify the following:
- Has the target's IP ownership been confirmed through employment agreements and written invention assignment documentation?
- Has the target received grants or benefits from the Israel Innovation Authority, and have the conditions applicable to a change of control been identified and quantified?
- Have all required regulatory clearances – competition, sector-specific, and FDI in the buyer's home jurisdiction – been identified and built into the closing conditions and deal timeline?
- Has the withholding tax position been addressed with the Israeli Tax Authority, including the timing of any withholding certificate application?
- Do the target's constitutional documents contain enforceable drag-along provisions that will bind all shareholders to the agreed terms?
A share purchase of an Israeli company is the appropriate vehicle if:
- The target's contracts, licences, and regulatory approvals are held at company level and are not transferable on an asset deal basis.
- The buyer has the capacity to manage inherited liabilities through appropriate SPA indemnities and representations and warranties insurance.
- The buyer has confirmed that no sector-specific restriction on foreign ownership applies to the target's activities.
An asset acquisition may be preferable if the buyer wishes to acquire specific assets rather than the full company, provided the employment and IP implications of that structure have been assessed under Israeli law.
The matter shifts from a straightforward private acquisition to a regulated transaction. typically requiring sector approvals, competition clearance. Alternatively. Securities law compliance. when the target operates in a regulated industry, when the combined entity exceeds competition law thresholds. Alternatively, when the target has publicly traded shares.
A detailed breakdown of the formation and governance requirements that precede many Israeli M&A transactions is available in our guide to company formation in Israel.
Frequently asked questions
Q: How long does a private M&A transaction in Israel typically take from signing to closing?
A: A private share acquisition in Israel without regulatory complications typically closes within three to six months of the letter of intent. Transactions requiring competition clearance or sector-specific approvals – such as those in financial services, communications, or defence-adjacent technology – extend this timeline considerably. In complex cases, six to twelve months is more realistic. Building accurate timeline estimates into the deal structure requires identifying all required approvals before exclusivity is granted.
Q: Is warranty and indemnity insurance commonly used in Israeli deals, and does it affect how representations and warranties are negotiated?
A: Warranty and indemnity insurance is used with increasing frequency in Israeli transactions, particularly in venture capital-backed exits where the seller seeks a clean break. Its availability does affect the negotiation dynamic: sellers may be willing to accept broader representations in the SPA if they know the exposure is insured. While insurers will conduct their own underwriting review of the due diligence process. The decision to pursue insurance should be made early – ideally before the SPA is first drafted – so the diligence process satisfies insurer requirements from the outset.
Q: Can a foreign entity acquire 100% of an Israeli company without restriction?
A: In the majority of sectors, a foreign entity can acquire 100% of an Israeli company without restrictions specific to the buyer's nationality. However, restrictions apply in sectors defined as sensitive under Israeli law – including certain defence-related activities, broadcasting, and banking – where prior government approval or ownership caps may limit foreign control. Engaging a lawyer in Israel with cross-border experience is essential to confirm the applicable regime before structuring the acquisition, as these restrictions are subject to change and are sector-specific rather than general.
About Ferraz & Whitmore
Ferraz & Whitmore is an international law firm based in Lisbon, advising business clients across 46 jurisdictions. Our team combines Portuguese civil law expertise with English common law tradition to deliver cross-border legal solutions in M&A transactions in Israel and across the Asia-Pacific and Middle East region. As an international law firm working across Israel, the UAE. Additionally, EU markets, we support international entrepreneurs, institutional investors. Additionally. In-house legal teams who require results-oriented counsel on share purchase agreements, due diligence, closing conditions, and post-closing integration. The firm's M&A practice covers transactions across both civil law and common law systems, supported by a network of local counsel in Israel and the broader region. Our attorneys have advised on cross-border acquisition and investment matters involving Israeli targets across multiple sectors, including technology, financial services, and real estate. To discuss your M&A transaction in Israel or a related cross-border matter, contact us at info@ferrazwhitmore.com.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.